WuXi STA forms Strategic Partnership with Beta PharmaSTA will accelerate process R&D and manufacturing of late phase and commercial targets
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Beta Pharma, a biotech company focusing on innovative drug discovery and development in oncology, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Beta Pharma, leveraging its platform to accelerate process R&D and manufacturing of later phase and commercial production – utilizing the Marketing Authorization Holder (MAH) scheme.
Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development, and commercialization of innovative late stage therapies targeting oncology.
The company has a pedigree spanning some 20 years and its founder Dr. Xiaodong Zhang even participated in the molecular invention, development and listing in China of the first small molecule targeted anticancer drug, Icotinib. Today, Beta Pharma continues to expand its pipeline to integrate anticancer drugs and therapies,